Liquidity & Technical

Liquidity & Technical

After the 2025 derating (MOH fell from $306 in June 2025 to $122 in early 2026 on serial guidance cuts and Medicaid cost shocks), the tape has turned. Price closed $200.28 on 12 June 2026 — back 19.5% above the 200-day, with a golden cross printed 2 June 2026, RSI 62, and a positive MACD histogram. Conviction is muted: the rally is not confirmed by upside volume, realized vol is still 39.6%, and price sits in the lower half of the 52-week range. Liquidity is not the constraint at this $10.6B mid-cap; a 5% position is implementable for funds up to ~$3.8B over a five-day build at 20% of ADV.

The implementation answer first

Liquidity — capacity, not a paragraph

20-day ADV is $175.6M (~939K shares), 60-day ADV is $224.2M — about a turn higher reflecting wider participation through the post-crash repricing. Annual share turnover runs ~740% of the float, which is unusually high for a managed-care mid-cap and signals that this name has become a hedge-fund and event-driven battleground rather than a buy-and-hold core holding. Median 60-day daily range is 1.88%, below the 2% friction threshold but elevated against historical Molina norms — execution-friction cost is modest but real, and limit orders should respect the wider intraday bands. Zero zero-volume days in the last 60 sessions; coverage is clean. Bottom line: for a fund running disciplined participation limits this is a deep, fast tape — the technical question dominates the liquidity question.

Ten years of price, two regimes

The 10-year picture has two regimes. From 2017 through early 2024 MOH compounded steadily from the $50s to an all-time high of $420.75 in March 2024, with only the usual cyclical pullbacks. The break came in mid-2024 (death cross 4 June 2024) as the Medicaid redetermination cycle started to surface unfavorable risk-pool mix; it accelerated through July 2025 when an earnings shock collapsed the stock from $297 to $157 in a matter of weeks. Successive misses through October 2025 (-17.5% day on 23 Oct), February 2026 (-25.5% day on 6 Feb), and March 2026 dragged the name to a 52-week low of $122.65. The cycle low is now ~5 months old, the 50-day has crossed back above the 200-day on 2 June 2026, and price has reclaimed all four short-term moving averages. The April–June 2026 base around $130–200 looks like accumulation; whether it sustains depends on the November earnings cycle.

The recent tape — 18-month zoom with momentum

Three things stand out on the 18-month weekly. First, the July 2025 break of the 200-day was the regime change — price went from kissing the upper Bollinger at $322 in March to slicing through the lower band at $250 within two weeks. Second, the post-crash range from August 2025 onward is the entire investment case: $130 on the downside (re-tested four times), $200 on the upside (now). Every test of $130 has held. Third, the most recent six weeks have lifted price above all MAs and pushed RSI from the high-20s in March to 62 in June — the cleanest momentum impulse since the breakdown.

Momentum — RSI and MACD both bullish, but not yet stretched

RSI prints 62 — the highest reading since April 2025 — but well short of the 70 overbought threshold. Crucially the direction matters: RSI bottomed at 6.85 the week of 18 July 2025 (one of the lowest readings in the 10-year history) and has built a series of higher lows since August. That is textbook momentum reversal, but it is happening from a deeply oversold base, not a confirmed uptrend.

MACD line at +5.62 crossed back above the signal in late April 2026 and the histogram has expanded (+1.0 last week, accelerating from +0.6 three weeks ago). This is the same MACD that signaled the July 2025 collapse early — line broke -3 in early July, well before the worst of the drawdown. The signal has flipped, but the absolute level (+5.6) is only mid-range against the pre-crash regime peaks of +8, suggesting room before exhaustion.

Volume — the rally lacks confirmation

The three most recent volume spikes — Feb 2026 (-25.5%), Mar 2026 (-2.0% on 7× volume), and Oct 2025 (-17.5%) — were all distribution events tied to earnings disappointments. The recovery rally to $200 has come on no comparable upside volume signature — no single up-day in 2026 has approached 5× average volume. That is the cleanest piece of evidence the move is short-covering and tactical positioning rather than long-only re-entry. A confirming high-volume buying day above $215 would meaningfully strengthen the bull case; until it prints, treat the rally as unconfirmed.

Volatility regime — elevated, not extreme

Realized 30-day vol of 39.6% sits between the 10-year 50th percentile (31.4%) and 80th percentile (48.3%) — elevated but not crisis-level. ATR(14) of $4.80 implies a typical daily range of roughly 2.4% of price. Practical implication: position-size stops at least 1.0× ATR below entry (i.e., $4-5 wide), and expect single-day swings of 3-5% on any newsflow. Don't size as if this is the pre-July 2025 MOH that ran 18% vol.

Cross-reference to fundamentals

This is the inverse of the 2017–2024 setup. For seven years the technical story (steady compounding above a rising 200-day) lined up with the fundamental story (Medicaid expansion, premium growth, manageable medical loss ratios). The 2025 break occurred before most sell-side analysts cut numbers — the death cross of 24 June 2025 preceded the July guidance cut by two weeks, and the October and February follow-ons re-confirmed the trend each time. Right now, tape and tape-watchers are saying the worst is priced in (golden cross, RSI building, base holding $130) while the fundamental cycle is still mid-correction (medical-cost trend not yet stabilized per recent disclosures). When tape leads fundamentals into a turn, the appropriate response is to build slowly through invalidation levels, not to wait for confirmation that prints at the price.

Technical scorecard

The total of 0 reflects the genuine tension in the tape: the momentum and trend signals say the bottom is in, while volume, volatility, and the 52-week position say don't size as if this is a clean uptrend yet. That is the right posture for a fund right now.

Stance — neutral with a cautious-bullish lean over 3-6 months

The base case is that MOH has put in a cyclical bottom around $130 and is in the early stages of a reversal that, if it holds, retraces toward the August 2025 air-pocket fill at $260-280 over the next two to three quarters. The risk case is that the medical-cost trend re-accelerates at the November Q3 print and the $130 floor breaks, opening a re-test of the $122 low and potentially the post-COVID $100 zone. Liquidity is not the constraint — a fund can build or exit a 2-5% position cleanly. The constraint is technical timing and the absence of volume confirmation.

Above $215 (the next clean swing high from January 2026 and the underside of the prior $215-260 distribution zone) — confirms the bull case and opens $260-280 as the next target; raise size on a confirming volume close.

Below $172 (the rising 50-day SMA, the Bollinger middle band proxy, and prior consolidation support) — invalidates the reversal thesis; cut position back to watchlist and wait for $130 to re-test.

Implementation: watchlist with a scale-in framework — start a starter position only on a confirming reclaim of $215 on above-average volume, build toward target weight slowly across multiple sessions to respect the elevated realized vol, and use $172 as the hard stop. Do not chase from current levels at $200 without confirmation; the risk-reward at this rung is symmetric and the catalyst calendar (November Q3) is the binary that will set the next regime.